Full Press Release Details
BOULDER, Colo. , March 26, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX ), a leading muscle disease biopharmaceutical company, today announced that members of the management team will hold a live webcast to discuss top-line data of EDG-7500 from the Phase 2 CIRRUS-HCM 28-day trial in patients with obstructive or nonobstructive HCM on Wednesday, April 2, 2025 , at 8:30 am ET . The team is excited to be joined by two of the Company's CIRRUS-HCM investigators, who are world leaders in the care of patients with HCM. An accompanying slide presentation will also be available. To register for the live webcast and replay, please visit the Edgewise events page .
EDG-7500 is a novel oral, selective, cardiac sarcomere modulator, specifically designed to slow early contraction velocity and address impaired cardiac relaxation associated with hypertrophic cardiomyopathy (HCM) and other diseases of diastolic dysfunction. To learn more about CIRRUS-HCM, visit clinicaltrials.gov, NCT06347159 (Phase 2) .
About Edgewise Therapeutics
This press release contains hyperlinks to information that is not deemed to be incorporated by reference into this press release.
Edgewise Contacts Investors: Michael Carruthers , Chief Financial Officer [email protected]
Media: Maureen Franco , VP Corporate Communications [email protected]